Ironwood Paying $1bn For VectivBio To Extend Its GI Franchise Beyond Linzess

Phase III Data For Apraglutide Due In Late 2023

 
• By Mandy Jackson

Ironwood said it believes VectivBio’s once-weekly GLP-2 analog apraglutide is differentiated from Takeda’s once-daily Gattex in short bowel syndrome and could generate $1bn in peak sales.

White jigsaw puzzle pieces connecting together on a light blue background
Ironwood sees VectivBio's apraglutide as a good fit in its gastrointestinal portfolio • Source: Shutterstock

More from Deals

More from Business